Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, highlights data from the DREAMM-9 study (NCT04091126). This phase III study assessed the efficacy and safety of belantamab mafodotin plus VRd versus VRd alone in patients with transplant-ineligible newly diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
